Expect the report would talk up rgs Bubby..."This report has been commissioned by Regeneus and prepared and issued by Edison" Edisons initial valuation report was heavily criticised as an analyst for hire advert.
"Regeneus is in advanced discussions with a large Japanese company regarding licensing Progenza for the Japanese market. Guidance in the half-yearly report in February was for a deal to be signed by mid year" (H1-CY16...June 30)
The current report... "Regeneus anticipates finalising these discussions before the end of the current quarter" (June 30 2016). Do finalising discussions now = signed deal & secured manufacturing & commercial partnership? "The cash balance and loan arrangement will fund operations into Q217 (Dec 2016), by which time Regeneus expects to have finalised out-licensing its Progenza mesenchymal stem cell technology for the Japanese market." Now "finalised discussions" by June 30 2016 & signed finalised deal by Dec 2016? Has the signed deal date now been pushed back another 6 mos....to the end of cash runway? Or are rgs still on for delivery of "finalised signed Progenza licensing deal with large Japanese coy" by June 30? rgs have form of soft trial & IP anncs, analyst for hire reports & vague comms about the Japan deal to support SP before failing to deliver. If coy are not going to meet the June 30 signed deal deadline more puff is not going to support SP IMHO.
RGS Price at posting:
16.5¢ Sentiment: None Disclosure: Not Held
